New "Self-Identification" Requirement for Drug Establishments Due by December …

Under the Generic Drug User Fee Amendments (GDUFA) of 2012, FDA is authorized to collect application fees for certain companies identified in generic drug submissions, including Abbreviated New Drug Applications (ANDA) and Prior Approval Supplements (PAS), and from holders of type II DMFs. GDUFA is …